CYP — Cynata Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$59.88m
- AU$54.82m
- AU$0.23m
Annual income statement for Cynata Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.08 | 7 | 0.353 | 0.418 | 0.228 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 7.48 | 13 | 14.9 | 10.2 | 9.61 |
| Operating Profit | -7.4 | -6.01 | -14.5 | -9.81 | -9.38 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -7.69 | -5.45 | -14.3 | -9.74 | -9.39 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.69 | -5.45 | -14.3 | -9.74 | -9.39 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.69 | -5.45 | -14.3 | -9.74 | -9.39 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.69 | -5.45 | -14.3 | -9.74 | -9.39 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.061 | -0.038 | -0.098 | -0.054 | -0.046 |